Capital World Investors Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital World Investors raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,600,525 shares of the biopharmaceutical company's stock after acquiring an additional 92,101 shares during the quarter. Capital World Investors owned approximately 12.87% of Alnylam Pharmaceuticals worth $3,906,284,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $41,529,000. Truist Financial Corp lifted its holdings in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after buying an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after acquiring an additional 2,285 shares during the period. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC reiterated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Citigroup raised their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $1.98 during midday trading on Thursday, hitting $240.00. The company had a trading volume of 284,440 shares, compared to its average volume of 872,902. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a fifty day moving average of $247.62 and a two-hundred day moving average of $256.40. The company has a market cap of $31.22 billion, a price-to-earnings ratio of -110.75 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,984 shares of company stock worth $16,864,347. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.